



12th August, 2025

Corporate Relationship Department
M/s. BSE Ltd.
Mumbai – 400 001.
Scrip Code: **524816**

The Manager – Listing
M/s. National Stock Exchange of India Ltd.
MUMBAI – 400 051.
Scrip Code: **NATCOPHARM**

Dear Sir/Madam

Sub: Outcome of Board Meeting

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2025 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations") along with Limited Review Report of the Statutory Auditors. Please find enclosed herewith a copy of the same for your information.
2. Declared interim dividend of Rs.2/- (Rupees Two only) (100 %) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2025-26. The date for taking on record of its shareholders is eligible for the purpose of payment of interim dividend i.e., record date is fixed as Tuesday, the day of 19th August 2025. The payment of said interim dividend will start from 26th August 2025.
3. Approved increase in Authorised Capital of the Company to Rs.45,00,00,000/- (Rupees Forty-Five Crores) divided into 22,50,00,000 (Twenty-two Crores and Fifty lakh) Equity Shares of Rs. 2/- (Rupees Two) each, subject to approval of the Shareholders and consequently approved the alteration of Memorandum of Association to substitute the existing Clause V with the new Clause V which is subject to approval of Shareholders, brief details of the same are enclosed as Annexure – A.
4. Approved the Notice for the 42nd Annual General Meeting and authorised Sri V. C. Nannapaneni, Chairman and Managing Director for fixing the Date & time for the Financial Year 2024-2025 through Video Conference (VC) / other Audio Visual Means (OAVM).

A Copy of Press release is also enclosed for your information.

Meeting commenced at 11: 45 a.m. and concluded at 13:05 p.m.

Thanking you

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: as above



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Annexure A

S No.	Particulars	Remarks
1	Amendments to memorandum of association of listed entity, in brief	It is proposed to increase the authorised share capital of the Company, which is subject to the approval of the Shareholders of the Company, by substituting the existing Clause V of the Memorandum of Association with the new Clause V i.e., "V. The Authorised Capital of the Company is Rs. 45,00,00,000/- (Rupees Forty five Crores only) divided into 22,50,00,000 (Twenty two Crores and Fifty Lakhs) Equity Shares of Rs. 2/- (Rupees Two) each with power to increase, reduce, reorganize, consolidate, divide and/or sub-divide the share capital and re-classify them into several classes and attach thereto respectively, such preferential, priority, deferred, qualified or special rights, privileges, conditions or restrictions, whether in regard to dividend, voting, return of capital, distribution of assets or otherwise, as may be determined in accordance with the laws, rules, regulations or resolutions of the Company or provided for in the Articles of Associations of the Company."



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.

Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30-06-2025

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended		Year ended	
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
	Income				
1	Revenue from operations	13,289	12,210	13,626	44,295
2	Other income	617	663	481	3,545
3	Total income (1+2)	13,906	12,873	14,107	47,840
	Expenses				
	Cost of materials consumed	1,806	1,690	1,513	5,362
	Purchases of stock-in-trade	373	408	325	1,661
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	151	394	(36)	(125)
	Employee benefits expense	1,690	1,594	1,420	5,945
	Finance costs	32	102	52	239
	Depreciation, amortisation and impairment expenses (refer note 7)	576	983	441	2,352
	Other expenses	3,559	2,643	2,356	9,492
	Total expenses	8,187	7,814	6,071	24,926
5	Profit before tax for the period/ year (3-4)	5,719	5,059	8,036	22,914
6	Tax expense				
	(i) Current tax	1,157	1,064	1,436	4,376
	(ii) Deferred tax	(241)	(65)	(85)	(296)
	Total tax expense	916	999	1,351	4,080
7	Profit for the period/ year (5-6)	4,803	4,060	6,685	18,834
8	Other comprehensive income/ (loss) (net of tax)				
	(i). Items that will not be reclassified to profit or loss:				
	Remeasurement of defined benefit liability/(asset)	-	(78)	-	(78)
	Tax on remeasurement of defined benefit liability/(asset)	-	27	-	27
	Fair value changes of Equity investments through OCI	53	(233)	26	23
	Tax impact in Fair value changes on Equity investments through OCI	(7)	31	(4)	(6)
		46	(253)	22	(34)
	(ii). Items that will be reclassified to profit or loss:				
	Exchange differences on translating financial statements of foreign operations	347	71	(166)	(206)
		347	71	(166)	(206)
	Other comprehensive income/ (loss) for the period/ year, net of tax	393	(182)	(144)	(240)
9	Total comprehensive income for the period/ year (7+8)	5,196	3,878	6,541	18,594
10	Profit for the period/year attributable to:				
	Owners of the Company	4,807	4,066	6,685	18,854
	Non-controlling interests	(4)	(6)	-	(20)
11	Other comprehensive income for the period/ year attributable to:				
	Owners of the Company	393	(182)	(144)	(240)
	Non-controlling interests	-	-	-	-
12	Total comprehensive income for the period/ year attributable to:				
	Owners of the Company	5,200	3,884	6,541	18,614
	Non-controlling interests	(4)	(6)	-	(20)
13	Paid-up equity share capital (Face value of ₹2 each)	358	358	358	358
14	Other equity				75,712
15	Earnings per share (not annualised for the quarters) (Face value of ₹2 each)				
	Basic (in ₹)	26.84	22.70	37.32	105.26
	Diluted (in ₹)	26.84	22.70	37.32	105.26

See accompanying notes to the unaudited consolidated financial results.

Continued..



NATCO Pharma Limited

Segment reporting:

(₹ in millions except share data)

S.No.	Particulars	Quarter ended			Year ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
1	Segment revenue				
	a. Pharmaceuticals	12,942	12,060	13,470	43,689
	b. Agro chemicals	347	150	156	606
		13,289	12,210	13,626	44,295
	Add: Unallocated	-	-	-	-
	Total revenue from operations	13,289	12,210	13,626	44,295
2	Segment results				
	a. Pharmaceuticals	5,783	5,970	8,286	24,611
	b. Agro chemicals*	(32)	(809)	(198)	(1,458)
	Total segment result	5,751	5,161	8,088	23,153
	Less:				
	a. Finance costs	(32)	(102)	(52)	(239)
	b. Net unallocated (income)/expenditure	-	-	-	-
	Total profit before tax	5,719	5,059	8,036	22,914
3	Segment assets				
	a. Pharmaceuticals	54,626	53,994	48,882	53,994
	b. Agro chemicals	2,678	2,712	4,165	2,712
	Total segment assets	57,304	56,706	53,047	56,706
	Add:				
	a. Unallocated	34,687	29,602	20,929	29,602
	Total assets	91,991	86,308	73,976	86,308
4	Segment liabilities				
	a. Pharmaceuticals	7,401	6,320	6,154	6,320
	b. Agro chemicals	440	314	461	314
	Total segment liabilities	7,841	6,634	6,615	6,634
	Add:				
	a. Unallocated	2,833	3,551	2,290	3,551
	Total liabilities	10,674	10,185	8,905	10,185

Continued..

*During the quarter and year ended 31-03-2025, an impairment loss of INR 500 million was recognised on the property, plant and equipment of Agro Chemical Segment.



NATCO Pharma Limited

Notes to the unaudited consolidated financial results:

- 1) The unaudited consolidated financial results of NATCO Pharma Limited ("the Company") and its subsidiaries (together referred as "the Group") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited consolidated financial results for the quarter ended 30-06-2025 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 12-08-2025.
- 3) The unaudited consolidated financial results of the Group for the quarter ended 30-06-2025, have been review by the statutory auditors and they have issued an unmodified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The consolidated figures for the quarter ended 31-03-2025 as reported in these unaudited consolidated financial results are the balancing figures between consolidated audited figures in respect of the full financial years and the published unaudited year to date consolidated figures up to the third quarter of the previous financial year. Also, the consolidated figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.
- 5) The unaudited consolidated financial results for the quarter ended 30-06-2025 includes financial results of the following subsidiaries/step-down subsidiaries:

S.No	Name of the entity	Country	Relationship
1	NATCO Pharma Inc.	United States of America	Wholly owned Subsidiary
2	NATCO Pharma USA LLC	United States of America	Step-down Subsidiary
3	Time Cap Overseas Limited	Mauritius	Wholly owned Subsidiary
4	NatcoFarma do Brasil Ltda.	Brazil	Step-down Subsidiary
5	NATCO Pharma (Canada) Inc.	Canada	Wholly owned Subsidiary
6	NATCO Pharma Asia Pte. Ltd.	Singapore	Wholly owned Subsidiary
7	NATCO Pharma Australia PTY Ltd.	Australia	Wholly owned Subsidiary
8	NATCO Lifesciences Philippines Inc.	Philippines	Wholly owned Subsidiary
9	NATCO Pharma UK Limited	United Kingdom	Wholly owned Subsidiary
10	PT.NATCO Lotus Farma	Indonesia	Subsidiary
11	NATCO Pharma Colombia S.A.S.	Colombia	Wholly owned Subsidiary

- 6) The unaudited standalone financial results, for the quarter ended 30-06-2025 can be viewed on the website of the Company, NSE and BSE at www.natcopharma.co.in, www.nseindia.com, and www.bseindia.com respectively. Information of unaudited standalone financial results of the Company in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

Particulars	Quarter ended			Year ended
	30-06-2025	31-03-2025	30-06-2024	30-06-2025
	Unaudited	Audited	Unaudited	Audited
Total income	12,523	12,195	12,767	44,158
Profit before tax	5,429	5,208	7,580	22,260
Net profit for the period/ year	4,641	4,281	6,363	18,504
Total comprehensive income for the period/ year	4,680	4,049	6,385	18,491

- 7) During the quarter and year ended 31 March 2025, the Group recognised an impairment loss of ₹ 500 million on account of impairment of property, plant and equipment of Agro chemical segment.
- 8) The Board of Directors at their meeting held on 12-08-2025 had approved an interim dividend of ₹ 2/- per equity share of ₹ 2 each for the quarter ended 30-06-2025.

**By order of the Board
For NATCO Pharma Limited**

V C Nannapaneni
Chairman & Managing Director
(DIN: 00183315)

Place: Hyderabad
Date: 12 August 2025

Limited Review Report on unaudited consolidated financial results of NATCO Pharma Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of NATCO Pharma Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of NATCO Pharma Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities :

Name of the entity	Relationship
NATCO Pharma Limited	Parent
NATCO Pharma Inc., United States of America ('USA')	Subsidiary
NATCO Pharma USA LLC, USA (Subsidiary of NATCO Pharma Inc.)	Step-down Subsidiary
Time Cap Overseas Limited, Mauritius ('TCOL')	Subsidiary
NatcoFarma do Brasil Ltda., Brazil (Subsidiary of TCOL)	Step-down Subsidiary
NATCO Pharma (Canada) Inc., Canada	Subsidiary

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

NATCO Pharma Limited

NATCO Pharma Asia Pte. Ltd., Singapore	Subsidiary
NATCO Pharma Australia PTY Ltd., Australia	Subsidiary
NATCO Lifesciences Philippines Inc., Philippines	Subsidiary
NATCO Pharma UK Limited, United Kingdom	Subsidiary
PT. NATCO Lotus Farma, Indonesia	Subsidiary
NATCO Pharma Colombia S.A.S.	Subsidiary

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial information of 11 subsidiaries/ step down subsidiaries included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of INR 1,620 million, total net profit after tax (before consolidation adjustments) of INR 147 million and total comprehensive income (before consolidation adjustments) of INR 154 million, for the quarter ended 30 June 2025, as considered in the Statement. These interim financial information has been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

These subsidiaries/ step down subsidiaries are located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the interim financial information of such subsidiaries/ step down subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries/ step down subsidiaries located outside India is based on the reports of other auditors and the conversion adjustments prepared by the management of the Parent and reviewed by us.



B S R and Co

Limited Review Report (Continued)


NATCO Pharma Limited

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W



Amit Kumar Bajaj

Partner

Hyderabad

12 August 2025

Membership No.: 218685

UDIN:25218685BMMKEK8978



NATCO Pharma Limited

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034

Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30-06-2025

(₹ in millions except per share data)

S.No.	Particulars	Quarter ended			Year ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		Unaudited	Audited (Refer note 4)	Unaudited	Audited
	Income				
1	Revenue from operations	11,927	11,574	12,369	40,945
2	Other income	596	621	398	3,213
3	Total income (1+2)	12,523	12,195	12,767	44,158
4	Expenses				
	Cost of materials consumed	1,806	1,690	1,513	5,362
	Purchases of stock-in-trade	79	97	77	455
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(48)	429	(134)	116
	Employee benefits expense	1,435	1,387	1,202	5,153
	Finance costs	26	88	44	196
	Depreciation, amortisation and impairment expense (refer note 7 below)	538	937	404	2,200
	Other expenses	3,258	2,359	2,081	8,416
	Total expenses	7,094	6,987	5,187	21,898
5	Profit before tax for the period/ year (3-4)	5,429	5,208	7,580	22,260
6	Tax expense				
	(i) Current tax	1,060	994	1,324	4,075
	(ii) Deferred tax	(272)	(67)	(107)	(319)
	Total tax expense	788	927	1,217	3,756
7	Profit for the period/ year (5-6)	4,641	4,281	6,363	18,504
8	Other comprehensive income/ (loss) (net of tax)				
	Items that will not be reclassified to profit or loss:				
	Remeasurement of defined benefit liability/(asset)	-	(78)	-	(78)
	Tax on remeasurement of defined benefit liability/(asset)	-	27	-	27
	Fair value changes in Equity investments through OCI	46	(212)	26	44
	Tax impact of Fair value changes in Equity investments through OCI	(7)	31	(4)	(6)
	Other comprehensive income/ (loss) for the period/ year, net of tax	39	(232)	22	(13)
9	Total comprehensive income for the period/ year (7+8)	4,680	4,049	6,385	18,491
10	Paid-up equity share capital (Face value of ₹2 each)	358	358	358	358
11	Other equity				72,981
12	Earnings per share (not annualised for the quarters) (Face value of ₹2 each)				
	Basic (in ₹)	25.91	23.90	35.53	103.31
	Diluted (in ₹)	25.91	23.90	35.53	103.31

See accompanying notes to the unaudited standalone financial results.

Continued..



NATCO Pharma Limited

Notes to the unaudited standalone financial results:

- 1) The unaudited standalone financial results of NATCO Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The unaudited standalone financial results for the quarter ended 30-06-2025 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 12-08-2025.
- 3) The unaudited standalone financial results of the Company for the quarter ended 30-06-2025, have been reviewed by the statutory auditors and they have issued an unmodified review report on the same. The review report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The standalone figures for the quarter ended 31-03-2025 as reported in these unaudited standalone financial results are the balancing figures between standalone audited figures in respect of the full previous financial year and the published unaudited year to date standalone figures up to the third quarter of the previous financial year. Also, the figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.
- 5) Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the unaudited consolidated financial results.
- 6) The unaudited financial results of the following subsidiaries and step-down subsidiaries of the Company are included in the consolidated financial results for the quarter ended 30-06-2025:

S.No	Name of the entity	Country	Relationship
1	NATCO Pharma Inc.	United States of America	Wholly owned Subsidiary
2	NATCO Pharma USA LLC	United States of America	Step-down Subsidiary
3	Time Cap Overseas Limited	Mauritius	Wholly owned Subsidiary
4	NatcoFarma do Brasil Ltda.	Brazil	Step-down Subsidiary
5	NATCO Pharma (Canada) Inc.	Canada	Wholly owned Subsidiary
6	NATCO Pharma Asia Pte. Ltd.	Singapore	Wholly owned Subsidiary
7	NATCO Pharma Australia PTY Ltd.	Australia	Wholly owned Subsidiary
8	NATCO Lifesciences Philippines Inc.	Philippines	Wholly owned Subsidiary
9	NATCO Pharma UK Limited	United Kingdom	Wholly owned Subsidiary
10	PT.NATCO Lotus Farma	Indonesia	Subsidiary
11	NATCO Pharma Colombia S.A.S.	Colombia	Wholly owned Subsidiary

- 7) During the quarter and year ended 31-03-2025, the Company recognised an impairment loss of ₹ 500 million on account of impairment of property, plant and equipment of Agro Chemical segment.
- 8) The Board of Directors at their meeting held on 12-08-2025 had approved an interim dividend of ₹ 2/- per equity share of ₹ 2 each for the quarter ended 30-06-2025.

**By order of the Board
For NATCO Pharma Limited**

V C Nannapaneni

Chairman & Managing Director
(DIN: 00183315)

Place: Hyderabad
Date: 12 August 2025

Limited Review Report on unaudited standalone financial results of NATCO Pharma Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of NATCO Pharma Limited (hereinafter referred to as “the Company”) for the quarter ended 30 June 2025 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it



Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

B S R and Co

Limited Review Report (Continued)

NATCO Pharma Limited

contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W


Amit Kumar Bajaj

Partner

Hyderabad

12 August 2025

Membership No.: 218685

UDIN:25218685BMMKEJ7113

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, August 12th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for first quarter of financial year 2026.

NATCO records ₹1,390.6 Crore consolidated revenue and ₹480.3 Crore of profit after tax for Q1FY26

NATCO recorded consolidated total revenue of INR 1,390.6 Crore for the quarter ended on 30th June, 2025 as against INR 1,410.7 crore as of 30th June, 2024. EBITDA for the quarter was at INR 632.7 Crore with margins at 45.5%. The net profit for the period, on a consolidated basis was INR 480.3 Crore.

During the quarter, the business faced pricing pressure in the US product portfolio and incurred increased R&D expenses on account of high value projects.

The Board of Directors have declared an interim dividend of INR 2 per equity share of INR 2 each during Q1FY26.

Segmental Revenue Split (INR Cr)

Segment	Q1FY26	Q4FY25	Q1FY25
Active Pharmaceutical Ingredients (API)	52.6	46.4	39.2
Domestic Formulations	107	99.4	102.2
Formulations export (Incl. profit share and subs)	1,126.5	1,052.5	1,210.1
Crop Health Sciences (CHS)	34.7	15.0	15.6
Other operating and non-operating income	69.8	74.0	43.6
Total	1,390.6	1,287.3	1,410.7

NATCO Pharma Ltd

NATCO House

Road No.2, Banjara Hills

Hyderabad-500 034, India

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter)

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in

Rajesh Chebiyam, EVP - CHS

rajesh.chebiyam@natcopharma.co.in

Earnings Call Details:

- *Date: 13th August 2025, Wednesday*
- *Time: 11 AM IST*
- **Dial-in-Numbers:**
 - *India: (+91 22) 62801222 / 71158123*
 - *US: 18667462133*
 - *UK: 08081011573*
 - *Singapore: 8001012045*
- *Pre-register using the link:*
<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6402328&linkSecurityString=301158e510>